Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial
Authors
Casali, PReichardt, P
Kang, Y
Blay, J
Joensuu, H
Maki, R
Rutkowski, P
Hohenberger, P
Gelderblom, H
Leahy, Michael G
von Mehren, M
Schoffski, P
Blackstein, M
Le Cesne, A
Badalamenti, G
Xu, J
Nishida, T
Laurent, D
Kuss, I
Demetri, G
Affiliation
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoIssue Date
2015
Metadata
Show full item recordCitation
Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. 2015, 26 (Suppl 6): 29 Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdv338.1Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdv338.1